DOCSLIB.ORG

Processing and Presentation of the Rheumatoid Arthritis Candidate Autoantigen Aggrecan, by Antigen- Specific B Cells

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Processing and Presentation of the Rheumatoid Arthritis Candidate Autoantigen Aggrecan, by Antigen- Specific B Cells Processing and presentation of the rheumatoid arthritis candidate autoantigen aggrecan, by antigen- specific B cells Caroline Louise Wilson A thesis submitted for the degree of Doctor of Philosophy Institute of Cellular Medicine Newcastle University September 2010 Abstract The proteoglycan aggrecan, which is a major structural component of cartilage, has been identified as a candidate autoantigen in rheumatoid arthritis (RA). This is principally due to its degradation early in the disease pathology, its ability to induce an RA-like disease in mouse models and the presence of elevated numbers of reactive T and B cells in RA patients. Studies have also defined an essential requirement for autoantigen-specific B cells as antigen presenting cells (APC) in RA although the cellular mechanisms involved in antigen processing and presentation of joint-derived autoantigens by B cells remains unknown. To investigate the role of autoreactive B cells as APC in RA, I have used two complimentary approaches to generate B cells expressing an aggrecan-specific B cell receptor (BCR). The first was based on a modified monoclonal antibody production protocol and the second involved the transfection of B lymphoma cells with newly generated plasmids encoding an aggrecan-specific BCR. Using the second approach, I have successfully generated aggrecan-specific B cell lines (C71-4C5 and C71-5F10). I have shown that these B cells specifically bind aggrecan leading to efficient processing and the generation of the immunogenic T cell epitope 84-103 that is recognised by both aggrecan-specific T cell hybridomas and CD4+ T cells isolated from an aggrecan-specific TCR transgenic mouse. The aggrecan-specific B cells are able to present aggrecan at least 104 fold more efficiently than non-specific B cells, 102 fold more efficiently than macrophages and comparable to that seen by dendritic cells. By using a panel of inhibitors, I have also shown that the generation of the 84- 103/MHC complex by aggrecan-specific B cells requires an acidic environment, proteolysis by aspartic, serine and metalloproteinases and the “classical” pathway of MHC class II biosynthesis. During this PhD, I have highlighted a novel role for aggrecan-specific B cells as important APC involved in aggrecan-presentation, as well as elucidating a role for metalloproteinases in aggrecan processing and presentation by APC. ii Acknowledgements I would like to thank my supervisor and mentor John for all of his support, encouragement, boundless knowledge and friendship. To Andy for his endless B cell enthusiasm and helpful criticism which has helped me to develop this thesis. To James, Jane and the entire musculoskeletal research group for extending their help, support and advice. I would also like to say a special thanks to Derek and Jelena for their support during the writing of this thesis and for showing me that research really is the best job ever! I must give heartfelt thanks to my fantastic family for supporting and encouraging me throughout all of this PhD thankyou mam, dad, John and Anne. To my boys Andrew and James whom I love with all my heart, who make every day special and who always make me smile no matter what is thrown at me. And finally I would like to dedicate my thesis to Claire and thank her for her unbelievably endless support, patience, love and encouragement. iii Contents Page Abstract ii Acknowledgements iii Contents iv Figures xi Tables xv Abbreviations xvi 1. Introduction 1 1.1 Rheumatoid arthritis. 1 1.2 The synovial joint 5 1.2.1 Articular cartilage 5 1.2.2 Synovium 6 1. 3 The role of T cells in RA 8 1.3.1 Genetic evidence for T cell involvement 8 1.3.2 T cell depletion therapy in RA 10 1.3.3 CD4+ T cell activation and tolerance 11 1.3.4 T cell tolerance 11 1.3.5 The role of Th17/Treg cells in RA 14 1.4 The role of B cells in RA 17 1.4.1 B cell depletion therapy 17 1.4.2 Autoantibodies and their role in disease 18 1.4.3 The role of B cells in lymphoid neogenesis and T cell activation 19 1.4.4 B cells and cytokines 23 1.5 B cells as antigen presenting cells 25 1.5.1 Antigen uptake via BCR 26 1.5.2 The BCR complex 26 1.5.3 Additional B cell antigen receptors 28 1.5.4 B cell Tolerance 29 1.5.5 B cell tolerance breakdown 30 1.6 Autoantigen processing and presentation 32 1.6.1 Candidate autoantigens 32 1.6.2 Antigen uptake by APC 33 iv 1.6.3 MHC class II assembly and trafficking. 35 1.6.4 Antigenic peptide generation and loading of MHC class II molecules 36 1.6.4.1 Proteolysis 36 1.6.4.2 Intracellular pH 39 1.6.4.3 The antigen structure 40 1.6.5 Inhibition of the antigen processing and presentation pathway. 42 1.6.5.1 Cycloheximide and Brefeldin A 43 1.6.5.2 Ammonium chloride 44 1.6.5.3 Proteinase inhibitors 44 1.7 Proteoglycan aggrecan as a candidate joint autoantigen 48 1.7.1 Aggrecan structure and function 48 1.7.2 Aggrecan breakdown and turnover in disease 50 1.7.3 Proteoglycan induced arthritis 53 1.7.4 Humoral and cellular responses to aggrecan in RA patients. 56 1.8 Aims of the project 58 2. Materials and Methods 59 2.1. Antigens 59 2.1.1 Bovine Aggrecan Preparation 59 2.1.1.2 Dissection 59 2.1.1.3 Proteoglycan separation by caesium chloride gradient 59 2.1.1.4 Deglycosylation 60 2.1.1.5 Quantification 60 2.1.1.6 SDS –polyacrylamide gel electrophoresis 60 2.1.1.7 Viscometry 61 2.1.1.8 ELISA 61 2.1.1.9 Biotinylation 62 2.1.1.10 Reduction and alkylation of aggrecan. 62 2.1.2 Recombinant tetanus toxin C fragment (TTCF). 62 2.1.3 Peptides 62 2.2 Cell lines and culture 63 2.3 Cryopreservation of cells. 64 2.3.1 Freezing cells 64 2.3.2 Thawing cells 64 v 2.4 Single cell cloning 64 2.5 Preparation of bone marrow derived dendritic cells for use as APC 65 2.6 Preparation of bone marrow derived macrophages for use as APC 65 2.7 Animals 66 2.8 Immunisations 66 2.9 Generation of immortalized aggrecan-specific B cells by fusion with 67 A20-1 HS lymphoma cells. 2.9.1 Fusion 1 immunisation 67 2.9.2 Fusion 2 immunization 67 2.9.3 Splenocyte/A20-1 HS fusion 67 2.9.4 The use of CD40L transfectants to expand splenic B cells prior to fusion. 68 2.10 Fusion screening 69 2.10.1 Flow cytometry 69 2.10.2 Antigen presentation assay 71 2.10.3 IL-2 bioassay 71 2.11 Antigen presentation assay (fixed APC system) 72 2.11.1 Pre-fixation of APC 72 2.11.2 Post-fixation of APC 72 2.12 Inhibitors of antigen processing 73 2.13 Construction of plasmids encoding aggrecan-specific BCR. 74 2.13.1 Cell lines and plasmids 74 2.13.2 Characterisation of the C71 and 1-C-6 antibodies by ELISA 74 2.13.3 RNA extraction 75 2.13.4 Rapid amplification of cDNA ends 75 2.13.5 Cloning 77 2.13.6 Plasmid DNA isolation 79 2.13.7 DNA sequencing 79 2.13.8 Maxi preps 79 2.13.9 Restriction digests. 80 2.13.10 Gel extraction/purification 81 2.13.11 DNA ligation 81 2.13.12 PCR to introduce restriction sites required for subsequent cloning steps. 81 2.14 Transfection with the aggrecan-specific BCR plasmids 83 vi 2.14.1 Transient transfection of plasmids containing C71/ 1-C-6 BCR 83 into HeLa cells. 2.14.2 Amaxa electroporation 83 2.15 A20-1 HS generation of stable cell transfectants. 84 2.16 Transfectant analysis 85 2.16.1 HeLa transfectant Immunofluorescence 85 2.16.2 A20-1 HS transfectant screening (Flow cytometry). 85 2.16.3 A20-1 HS transfectant screening (Antigen presentation). 86 2.17 Generation of aggrecan-specific T cell hybridomas 87 2.17.1 Immunisation, cell isolation and in vitro re-stimulation. 87 2.16.2 T cell fusion 88 2.17 Cytokine analysis of CD4+ T cells from TCR-5/4E8-tg mice. 89 2.17.1 CD4+ T cell isolation 89 2.17.2 Flow cytometry to determine purity and TCR Vβ4 usage of the 89 isolated CD4+ T cells. 2.17.3 Cytokine analysis 90 2.18 Statistical analysis 91 3. Generation of immortalized aggrecan-specific B cells by fusion with 92 A20-1 HS lymphoma cells. 3.1 Introduction 92 3.1.2 The aims of this chapter 94 3.2 Results 95 3.2.1 Immunisation and cell fusion. 95 3.2.2 Characterisation of fusion cells by flow cytometry and 98 antigen presentation. 3.2.2.1 Flow cytometry 98 3.2.2.2 Antigen presentation assay. 101 3.2.2.3 Detection of aggrecan binding to fusions by flow cytometry. 109 3.2.2.4 Presentation of p84-103 and deglycosylated aggrecan to 112 T cell hybridomas 192 by fusion clones 53.28 and 24.14 in the presence of anti-Ig, anti-class II or anti-Fc to block presentation. 3.2.2.4 Ig characterisation by ELISA. 114 3.2.2.5 Is aggrecan presentation improved due to the extracellular proteinases? 116 vii 3.2.2.6 Aggrecan presentation to T cell hybridomas specific for epitopes 119 within the G3 domain.
Load more

Recommended publications
  • TACI:Fc Scavenging B Cell Activating Factor (BAFF) Alleviates Ovalbumin-Induced Bronchial Asthma in Mice
    EXPERIMENTAL and MOLECULAR MEDICINE, Vol. 39, No. 3, 343-352, June 2007 TACI:Fc scavenging B cell activating factor (BAFF) alleviates ovalbumin-induced bronchial asthma in mice 1,2,3 2 Eun-Yi Moon and Sook-Kyung Ryu the percentage of non-lymphoid cells and no changes were detected in lymphoid cell population. 1 Department of Bioscience and Biotechnology Hypodiploid cell formation in BALF was decreased Sejong University by OVA-challenge but it was recovered by TACI:Fc Seoul 143-747, Korea treatment. Collectively, data suggest that asthmatic 2 Laboratory of Human Genomics symptom could be alleviated by scavenging BAFF Korea Research Institute of Bioscience and Biotechnology (KRIBB) and then BAFF could be a novel target for the Daejeon 305-806, Korea develpoment of anti-asthmatic agents. 3 Corresponding author: Tel, 82-2-3408-3768; Fax, 82-2-466-8768; E-mail, [email protected] Keywords: asthma; B-cell activating factor; ovalbu- and [email protected] min; transmembrane activator and CAML interactor protein Accepted 28 March 2007 Introduction Abbreviations: BAFF, B cell activating factor belonging to TNF- family; BALF, bronchoalveolar lavage fluid; OVA, ovalbumin; PAS, Mature B cell generation and maintenance are regu- periodic acid-Schiff; Prx, peroxiredoxin; TACI, transmembrane lated by B-cell activating factor (BAFF). BAFF is pro- activator and calcium modulator and cyclophilin ligand interactor duced by macrophages or dendritic cells upon stim- ulation with LPS or IFN- . BAFF belongs to the TNF family. Its biological role is mediated by the specific Abstract receptors, B-cell maturation antigen (BCMA), trans- membrane activator and calcium modulator and cy- Asthma was induced by the sensitization and chal- clophilin ligand interactor (TACI) and BAFF receptor, lenge with ovalbumin (OVA) in mice.
    [Show full text]
  • Aggrecan (A1960)
    Aggrecan from bovine articular cartilage Catalog Number A1960 Storage Temperature –20 °C Product Description References Aggrecan is the major structural proteoglycan found in 1. Hardingham, T.E., and Muir, H., Biochim. Biophys. the extracellular matrix of cartilage. It has a molecular Acta, 279, 401-405 (1972). mass >2,500 kDa. The core protein (210–250 kDa) has 2. Hedlund, H., et al., Association of the aggrecan 100–150 glycosaminoglycan (GAG) chains attached to keratan sulfate-rich region with collagen in bovine it. The majority of the GAG chains are chondroitin/ articular cartilage. J. Biol. Chem., 274, 5777-5781 dermatan sulfate with the remainder being keratan (1999). sulfate. This structural molecule produces a rigid, 3. Cao, L., and Yang, B.B., Chondrocyte apoptosis reversibly deformable gel that resists compression. It induced by aggrecan G1 domain as a result of combines with hyaluronic acid to form very large decreased cell adhesion. Exp. Cell Res., 246, 527- macromolecular complexes. Addition of small amounts 537 (1999). (0.1–2% w/w) of hyaluronic acid to a solution of 4. Bolton, M.C., et al., Age-related changes in the aggrecan (2 mg/ml) results in the formation of a synthesis of link protein and aggrecan in human complex with an increased hydrodynamic volume and articular cartilage: implications for aggregate in a significant increase (30–40%) in the relative stability. Biochem. J., 337, 77-82 (1999). viscosity of the solution. 5. Arner, E.C., et al., Generation and Characterization of Aggrecanase. A soluble, cartilage-derived Aggrecan is a critical component for cartilage structure aggrecan-degrading activity.
    [Show full text]
  • The Brain Chondroitin Sulfate Proteoglycan Brevican Associates with Astrocytes Ensheathing Cerebellar Glomeruli and Inhibits Neurite Outgrowth from Granule Neurons
    The Journal of Neuroscience, October 15, 1997, 17(20):7784–7795 The Brain Chondroitin Sulfate Proteoglycan Brevican Associates with Astrocytes Ensheathing Cerebellar Glomeruli and Inhibits Neurite Outgrowth from Granule Neurons Hidekazu Yamada, Barbara Fredette, Kenya Shitara, Kazuki Hagihara, Ryu Miura, Barbara Ranscht, William B. Stallcup, and Yu Yamaguchi The Burnham Institute, La Jolla, California 92037 Brevican is a nervous system-specific chondroitin sulfate surface of these cells. Binding assays with exogenously proteoglycan that belongs to the aggrecan family and is one added brevican revealed that primary astrocytes and several of the most abundant chondroitin sulfate proteoglycans in immortalized neural cell lines have cell surface binding sites adult brain. To gain insights into the role of brevican in brain for brevican core protein. These cell surface brevican binding development, we investigated its spatiotemporal expression, sites recognize the C-terminal portion of the core protein and cell surface binding, and effects on neurite outgrowth, using are independent of cell surface hyaluronan. These results rat cerebellar cortex as a model system. Immunoreactivity of indicate that brevican is synthesized by astrocytes and re- brevican occurs predominantly in the protoplasmic islet in tained on their surface by an interaction involving its core the internal granular layer after the third postnatal week. protein. Purified brevican inhibits neurite outgrowth from Immunoelectron microscopy revealed that brevican is local- cerebellar granule neurons in vitro, an activity that requires ized in close association with the surface of astrocytes that chondroitin sulfate chains. We suggest that brevican pre- form neuroglial sheaths of cerebellar glomeruli where incom- sented on the surface of neuroglial sheaths may be control- ing mossy fibers interact with dendrites and axons from ling the infiltration of axons and dendrites into maturing resident neurons.
    [Show full text]
  • T Cell Reactivity + Autoantibodies and CD4 Therapy Is Mediated By
    Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4 + T Cell Reactivity This information is current as of September 27, 2021. Keith Hamel, Paul Doodes, Yanxia Cao, Yumei Wang, Jeffrey Martinson, Robert Dunn, Marilyn R. Kehry, Balint Farkas and Alison Finnegan J Immunol 2008; 180:4994-5003; ; doi: 10.4049/jimmunol.180.7.4994 Downloaded from http://www.jimmunol.org/content/180/7/4994 References This article cites 48 articles, 20 of which you can access for free at: http://www.jimmunol.org/ http://www.jimmunol.org/content/180/7/4994.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists by guest on September 27, 2021 • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2008 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Suppression of Proteoglycan-Induced Arthritis by Anti-CD20 B Cell Depletion Therapy Is Mediated by Reduction in Autoantibodies and CD4؉ T Cell Reactivity1 Keith Hamel,* Paul Doodes,* Yanxia Cao,† Yumei Wang,† Jeffrey Martinson,* Robert Dunn,§ Marilyn R.
    [Show full text]
  • Syndecan - Regulation and Function of Its Glycosaminoglycan Chains
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 884 Syndecan - Regulation and Function of its Glycosaminoglycan Chains ANNA S. ERIKSSON ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-8637-2 UPPSALA urn:nbn:se:uu:diva-197691 2013 Dissertation presented at Uppsala University to be publicly examined in A1:107a, BMC, Husargatan 3, Uppsala, Friday, May 17, 2013 at 13:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in English. Abstract Eriksson, A. S. 2013. Syndecan - Regulation and Function of its Glycosaminoglycan Chains. Acta Universitatis Upsaliensis. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 884. 54 pp. Uppsala. ISBN 978-91-554-8637-2. The cell surface is an active area where extracellular molecules meet their receptors and affect the cellular fate by inducing for example cell proliferation and adhesion. Syndecans and integrins are two transmembrane molecules that have been suggested to fine-tune these activities, possibly in cooperation. Syndecans are proteoglycans, i.e. proteins with specific types of carbohydrate chains attached. These chains are glycosaminoglycans and either heparan sulfate (HS) or chondroitin sulfate (CS). Syndecans are known to influence cell adhesion and signaling. Integrins in turn, are important adhesion molecules that connect the extracellular matrix with the cytoskeleton, and hence can regulate cell motility. In an attempt to study how the two types of glycosaminoglycans attached to syndecan-1 can interact with integrins, a cell based model system was used and functional motility assays were performed. The results showed that HS, but not CS, on the cell surface was capable of regulating integrin-mediated cell motility.
    [Show full text]
  • Fibroblasts from the Human Skin Dermo-Hypodermal Junction Are
    cells Article Fibroblasts from the Human Skin Dermo-Hypodermal Junction are Distinct from Dermal Papillary and Reticular Fibroblasts and from Mesenchymal Stem Cells and Exhibit a Specific Molecular Profile Related to Extracellular Matrix Organization and Modeling Valérie Haydont 1,*, Véronique Neiveyans 1, Philippe Perez 1, Élodie Busson 2, 2 1, 3,4,5,6, , Jean-Jacques Lataillade , Daniel Asselineau y and Nicolas O. Fortunel y * 1 Advanced Research, L’Oréal Research and Innovation, 93600 Aulnay-sous-Bois, France; [email protected] (V.N.); [email protected] (P.P.); [email protected] (D.A.) 2 Department of Medical and Surgical Assistance to the Armed Forces, French Forces Biomedical Research Institute (IRBA), 91223 CEDEX Brétigny sur Orge, France; [email protected] (É.B.); [email protected] (J.-J.L.) 3 Laboratoire de Génomique et Radiobiologie de la Kératinopoïèse, Institut de Biologie François Jacob, CEA/DRF/IRCM, 91000 Evry, France 4 INSERM U967, 92260 Fontenay-aux-Roses, France 5 Université Paris-Diderot, 75013 Paris 7, France 6 Université Paris-Saclay, 78140 Paris 11, France * Correspondence: [email protected] (V.H.); [email protected] (N.O.F.); Tel.: +33-1-48-68-96-00 (V.H.); +33-1-60-87-34-92 or +33-1-60-87-34-98 (N.O.F.) These authors contributed equally to the work. y Received: 15 December 2019; Accepted: 24 January 2020; Published: 5 February 2020 Abstract: Human skin dermis contains fibroblast subpopulations in which characterization is crucial due to their roles in extracellular matrix (ECM) biology.
    [Show full text]
  • Fibronectin Regulates Proteoglycan Production Balance in Transforming Growth Factor-Β1-Induced Chondrogenesis
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 28: 829-834, 2011 Fibronectin regulates proteoglycan production balance in transforming growth factor-β1-induced chondrogenesis TatsuHIKO KUTSUNA1,2, HIROFUMI INOUE2-4, HARUHIKO TAKEDA1, TOSHIAKI TAKAHASHI1, HARUYASU Yamamoto1, HIROMASA MIURA1 and SHIGEKI HIGASHIYAMA2,3 Departments of 1Bone and Joint Surgery and 2Biochemistry and Molecular Genetics, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295; 3Department of Cell Growth and Tumor Regulation, 4Ehime-Nikon Bioimaging Core Laboratory, Ehime Proteo Medicine Research Center (ProMRes), Ehime University, Shitsukawa, Toon, Ehime 791-0295, Japan Received May 23, 2011; Accepted June 22, 2011 DOI: 10.3892/ijmm.2011.766 Abstract. Transforming growth factor (TGF)-β and bone Introduction morphogenetic protein (BMP) induce a cartilage-specific extracellular matrix (ECM) gene, aggrecan, in a chondrogenic Cartilage is a firm connective tissue with high water-holding cell line, ATDC5. The results of our recent study show that capacity found in many parts of animal bodies, including the TGF-β1, but not BMP-4, strongly induces an ECM gene, joints, ears, nose, trachea, and intervertebral discs. Cartilage fibronectin, during chondrogenesis. However, the role of fibro- is composed of chondrocytes which produce copious extra- nectin in chondrogenesis is unclear. In the current study, our cellular matrix (ECM), including type I or II collagen fibres, results showed that TGF-β1, but not BMP-4, led to versican- proteoglycans, and elastin fibres. Cartilage is classified into dominant proteoglycan production during chondrogenesis of 3 types, elastic cartilage, hyaline cartilage and fibrocartilage, ATDC5 cells. siRNA-mediated reduction of fibronectin and which differ in the relative amounts of the above-mentioned interference in the liaison between fibronectin and integrins main components.
    [Show full text]
  • Studies of the Articular Cartilage Proteoglycan Aggrecan in Health and Osteoarthritis
    Studies of the articular cartilage proteoglycan aggrecan in health and osteoarthritis. Evidence for molecular heterogeneity and extensive molecular changes in disease. G Rizkalla, … , E Bogoch, A R Poole J Clin Invest. 1992;90(6):2268-2277. https://doi.org/10.1172/JCI116113. Research Article Changes in the structure of the proteoglycan aggrecan (PG) of articular cartilage were determined immunochemically by RIA and gel chromatography and related to cartilage degeneration documented histologically by the Mankin grading system. Monoclonal antibodies to glycosaminoglycan epitopes were used. In all cartilages, three chondroitin sulfate (CS)- rich populations of large size were observed in addition to a smaller keratan sulfate (KS)-rich population. In grades 7-13 OA cartilages (phase II), molecules were significantly larger than the equivalent molecules of grades 2-6 (phase I). CS chain lengths remained unchanged. In most OA cartilages, a CS epitope 846 was elevated in content, this being most marked in phase II (mean: fivefold). Loss of uronic acid, KS, and hyaluronic acid were only pronounced in phase II OA because of variations in normal contents. Aggregation of PG was unchanged (50-60%) or reduced in OA cartilages, but molecules bearing epitope 846 exhibited almost complete aggregation in normal cartilages. This study provides evidence for the capacity of OA cartilage to synthesize new aggrecan molecules to replace those damaged and lost by disease- related changes. It also defines two phases of PG change in OA: an early predominantly degenerate phase I followed by a net reparative phase II accompanied by net loss of these molecules. Find the latest version: https://jci.me/116113/pdf Studies of the Articular Cartilage Proteoglycan Aggrecan in Health and Osteoarthritis Evidence for Molecular Heterogeneity and Extensive Molecular Changes in Disease Geihan Rizkalla, * Agnes Reiner, * Earl Bogoch,t and A.
    [Show full text]
  • Cartilage Proteoglycans
    seminars in CELL & DEVELOPMENTAL BIOLOGY, Vol. 12, 2001: pp. 69–78 doi:10.1006/scdb.2000.0243, available online at http://www.idealibrary.com on Cartilage proteoglycans Cheryl B. Knudson∗ and Warren Knudson The predominant proteoglycan present in cartilage is the tural analysis. The predominate glycosaminoglycan large chondroitin sulfate proteoglycan ‘aggrecan’. Following present in cartilage has long been known to be its secretion, aggrecan self-assembles into a supramolecular chondroitin sulfate. 2 However, extraction of the structure with as many as 50 monomers bound to a filament chondroitin sulfate in a more native form, as a of hyaluronan. Aggrecan serves a direct, primary role pro- proteoglycan, proved to be a daunting task. The viding the osmotic resistance necessary for cartilage to resist revolution in the field came about through the compressive loads. Other proteoglycans expressed during work of Hascall and Sajdera. 3 With the use of the chondrogenesis and in cartilage include the cell surface strong chaotropic agent guanidinium hydrochlo- syndecans and glypican, the small leucine-rich proteoglycans ride, the proteoglycans of cartilage could now be decorin, biglycan, fibromodulin, lumican and epiphycan readily extracted and separated into relatively pure and the basement membrane proteoglycan, perlecan. The monomers through the use of CsCl density gradient emerging functions of these proteoglycans in cartilage will centrifugation. This provided the means to identify enhance our understanding of chondrogenesis and cartilage and characterize the major chondroitin sulfate pro- degeneration. teoglycan of cartilage, later to be termed ‘aggrecan’ following the cloning and sequencing of its core Key words: aggrecan / cartilage / CD44 / chondrocytes / protein. 4 From this start, aggrecan has gone on to hyaluronan serve as the paradigm for much of proteoglycan c 2001 Academic Press research.
    [Show full text]
  • The Interaction of Versican with Its Binding Partners
    YaoREVIEW Jiong WU et al The interaction of versican with its binding partners Yao Jiong WU1,3, David P. LA PIERRE1,3, Jin WU2, Albert J. YEE1, Burton B. YANG1,3,* 1Sunnybrook & Women’s College Health Sciences Centre, 2075 Bayview Avenue, Toronto M4N 3M5 Canada 2School of Chinese Medicine, The University of Hong Kong, Hong Kong SAR, China 3Department of Laboratory Medicine and Pathobiology, University of Toronto, Canada ABSTRACT Versican belongs to the family of the large aggregating chondroitin sulfate proteoglycans located primarily within the extracellular matrix (ECM). Versican, like other members of its family, has unique N- and C-terminal globular regions, each with multiple motifs. A large glycosaminoglycan-binding region lies between them. This review will begin by outlining these structures, in the context of ECM proteoglycans. The diverse binding partners afforded to versican by virtue of its modular design will then be examined. These include ECM components, such as hyaluronan, type I collagen, tenascin-R, fibulin-1, and -2, fibrillin-1, fibronectin, P- and L-selectins, and chemokines. Versican also binds to the cell surface proteins CD44, integrin β1, epidermal growth factor receptor, and P-selectin glycoprotein ligand-1. These multiple interactors play important roles in cell behaviour, and the roles of versican in modulating such processes are discussed. Keywords: extracellular matrix, proteoglycan, G3 domain, glycosaminoglycan, interaction. INTRODUCTION sub-group of the former, the large aggregating chondroitin The extracellular matrix (ECM) is a highly-ordered sulfate proteoglycans (which includes aggrecan, versican, supramacromolecular structure with many physiological neurocan and brevican), has been studied extensively [1-11]. and pathophysiological roles.
    [Show full text]
  • Evidence for Lysosomal Exocytosis and Release of Aggrecan-Degrading Hydrolases from Hypertrophic Chondrocytes, in Vitro and in Vivo
    318 Research Article Evidence for lysosomal exocytosis and release of aggrecan-degrading hydrolases from hypertrophic chondrocytes, in vitro and in vivo Edward R. Bastow1, Karena Last1, Sue Golub1, Jennifer L. Stow2, Amanda C. Stanley2 and Amanda J. Fosang1,* 1University of Melbourne Department of Paediatrics and Murdoch Childrens Research Institute, Royal Children’s Hospital, Flemington Road, Parkville, VIC 3052, Australia 2Institute for Molecular Bioscience, University of Queensland, Brisbane, QLD 4072, Australia *Author for correspondence ([email protected]) Biology Open 1, 318–328 doi: 10.1242/bio.2012547 Summary The abundant proteoglycan, aggrecan, is resorbed from growth b-hexosaminidase, ionomycin induces release of aggrecan- and plate cartilage during endochondral bone ossification, yet mice hyaluronan-degrading activity from cultured epiphyseal with genetically-ablated aggrecan-degrading activity have no chondrocytes. We identify VAMP-8 and VAMP7 as v-SNARE defects in bone formation. To account for this apparent proteins with potential roles in lysosomal exocytosis in anomaly, we propose that lysosomal hydrolases degrade hypertrophic chondrocytes, based on their colocalisation with extracellular, hyaluronan-bound aggrecan aggregates in LAMP1 at the cell surface in secondary ossification centers in growth plate cartilage, and that lysosomal hydrolases are mouse tibiae. We propose that resorbing growth plate cartilage released from hypertrophic chondrocytes into growth plate involves release of destructive hydrolases from hypertrophic cartilage via Ca2+-dependent lysosomal exocytosis. In this study chondrocytes, via lysosomal exocytosis. we confirm that hypertrophic chondrocytes release hydrolases via lysosomal exocytosis in vitro and we show in vivo evidence ß 2012. Published by The Company of Biologists Ltd. This is for lysosomal exocytosis in hypertrophic chondrocytes during an Open Access article distributed under the terms of the skeletal development.
    [Show full text]
  • Protective Role of the Alpha-1-Antitrypsin in Intervertebral Disc Degeneration Weikun Liu1 and Yanfu Wang2*
    Liu and Wang Journal of Orthopaedic Surgery and Research (2021) 16:516 https://doi.org/10.1186/s13018-021-02668-z RESEARCH ARTICLE Open Access Protective role of the alpha-1-antitrypsin in intervertebral disc degeneration Weikun Liu1 and Yanfu Wang2* Abstract Background: Intervertebral disc degeneration is a complex disease with high prevalence. It suggests that cell death, senescence, and extracellular matrix degradation are involved in the pathogenesis. Alpha-1 antitrypsin (AAT), a serine protease inhibitor, was previously correlated with inflammation-related diseases. However, its function on intervertebral disc degeneration remains unclear. Methods: A latex-enhanced immunoturbidimetric assay measured the serum level of AAT. Real-time polymerase chain reaction (RT-qPCR) and western blot were used to testify the expression of RNA and proteins related to cell apoptosis and the Wnt/β-catenin pathway. The animal model for intervertebral disc degeneration was built by disc puncture. The degeneration grades were analyzed by safranin o staining. Results: We showed that alpha-1 antitrypsin could ameliorate intervertebral disc degeneration in vitro and in vivo. We also found that the serum alpha-1 antitrypsin level in Intervertebral disc degeneration patients is negative related to the severity of intervertebral disc degeneration. Moreover, alpha-1 antitrypsin was also showed to suppress tumor necrosis factor-alpha (TNF-α) induced WNT/β-catenin signaling pathway activation in human nucleus pulposus cells. Conclusions: Our study provides evidence for AAT to serve as a potential therapeutic reagent for the treatment of intervertebral disc degeneration. Keywords: Intervertebral disc degeneration, Alpha-1 antitrypsin, Apoptosis, Extracellular matrix degradation, WNT/β-catenin signaling Introduction mechanism remain incompletely understood.
    [Show full text]